Tesamorelin 5 mg

Tesamorelin 5 mg contains tesamorelin, a growth hormone-releasing hormone analog. In medical practice, it is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In non-medical bodybuilding contexts, it is commonly referenced for body composition effects, though such use falls outside approved indications.

Tesamorelin is administered subcutaneously once daily. In bodybuilding contexts, evening injections are sometimes referenced to align with the body's natural GH secretion patterns. Medical dosing is individualized by a clinician.

No. Tesamorelin does not suppress the hypothalamic-pituitary-gonadal axis and does not require post-cycle therapy for testosterone recovery. It stimulates the growth hormone/IGF-1 axis, which is distinct from the hormonal pathways affected by anabolic steroids.

Tesamorelin binds to and stimulates GHRH receptors in the pituitary gland, promoting the synthesis and pulsatile release of endogenous growth hormone. This leads to increases in IGF-1 and IGFBP-3 levels. Clinical trials have demonstrated reductions in visceral adipose tissue, trunk fat, and waist circumference, alongside increases in lean body mass.

In clinical trials, significant changes in visceral adipose tissue and body composition were observed over 26 weeks of treatment. In bodybuilding discussions, some users reference noticeable effects on body composition within 4-8 weeks, though individual response varies and these timelines are based on non-medical user reports.

There is no universally "best" peptide for fat loss. Tesamorelin has the strongest clinical evidence for visceral fat reduction among GHRH analogs, but other peptides such as Ipamorelin and Sermorelin are also referenced in bodybuilding contexts. The appropriate choice depends on individual goals and clinical considerations.

Both tesamorelin and sermorelin are GHRH analogs that stimulate endogenous GH release, but they have different amino acid sequences and pharmacokinetic profiles. Tesamorelin has been extensively studied in clinical trials for visceral fat reduction in HIV-associated lipodystrophy, while sermorelin has been used for diagnostic purposes and GH deficiency. Axiolabs offers Sermorelin as its sermorelin product.

Tesamorelin is a GHRH receptor agonist, while ipamorelin is a ghrelin receptor agonist (GH secretagogue). They act through different receptors and pathways to stimulate GH release. Tesamorelin has clinical evidence for visceral fat reduction, while ipamorelin is referenced for its selective GH release without significant effects on cortisol or prolactin. Axiolabs offers Ipamorelin as its ipamorelin product.

In clinical trials, tesamorelin was studied at 2 mg daily. The FDA-approved dose for the current formulations is 1.28 mg (EGRIFTA WR) or 1.4 mg (EGRIFTA SV). In bodybuilding contexts, 2 mg is at the higher end of referenced ranges. Tesamorelin 5 mg contains 5 mg per vial, so a 2 mg dose would require reconstitution and measurement.

Tesamorelin 5 mg is supplied as 5 mg of tesamorelin per vial in a 2 mL vial. The lyophilized powder requires reconstitution before use.

Lab testing information for Tesamorelin 5 mg is not available on this page. For product-specific testing inquiries, please contact customer support.

Yes. Tesamorelin can increase glucose intolerance, and diabetes has been reported as an adverse effect. Blood sugar should be measured periodically during therapy, particularly in patients with diabetes or risk factors for glucose intolerance.